PMC · DOI:10.1038/s41392-024-01835-y·April 30, 2024
Harnessing naturally occurring mutations for T-cell therapy: a potential new avenue to enhance treatment efficacy
Michael Hiltensperger, Jürgen Ruland, Kilian Schober
Abstract
Linked entities
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Proteins18
Cell lines5
K562— Homo sapiens (Human) · Blast phase chronic myelogenous leukemia, BCR-ABL1 positive · Cancer cell linehCD19— Cricetulus griseus (Chinese hamster) · Spontaneously immortalized cell lineB16— Mus musculus (Mouse) · HybridomaNalm6— Homo sapiens (Human) · Adult B acute lymphoblastic leukemia · Cancer cell lineJurkat— Homo sapiens (Human) · Childhood T acute lymphoblastic leukemia · Cancer cell line
Chemicals1
Diseases9
Mutations1
G12D
Figures1
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCAR-T cell therapy research · CRISPR and Genetic Engineering · Virus-based gene therapy research